Clinical Trials Logo

Dry Mouth clinical trials

View clinical trials related to Dry Mouth.

Filter by:

NCT ID: NCT02123147 Withdrawn - Autoimmune Diseases Clinical Trials

Examining the Immunological Process of Autoimmune Patients

Start date: July 2014
Phase: N/A
Study type: Observational

Sjögren's syndrome (SjS) is an autoimmune disease characterized primarily by exocrine gland dysfunction, specifically of the salivary and lacrimal glands, resulting in dry mouth and dry eyes symptoms. It can be systemic by affecting other organs including the gastrointestinal tract, skin, lungs, vasculature, kidneys, bladder and vagina. Involvement of the musculature can lead to fibromyalgia-like symptoms and chronic fatigue, while approximately 20% of patients develop various neuropathies, including sensory, peripheral, cranial and myelopathic neuropathies exhibited by cognitive impairments such as dementia, lack of concentration, memory loss and various psychiatric disorders. Like most autoimmune connective tissue diseases, SjS shows a sexual dimorphism with women affected 10-times more frequently than men, suggesting a role for sex hormones in disease susceptibility or progression. One common feature of SjS is it infiltration of mononuclear cells into the salivary and lacrimal glands, aggregating into clusters referred to as lymphocytic foci (LF). Critical to the studies proposed is the fact that a predominant cell population of LF is the pathogenic TH17 cell that produces IL-17 cytokine and autoreactive B cells reactive to M3R, Ro, and La autoantigens. The goal of this study is characterize the change in receptor gene repertoires of autoreactive B and T cells at different time points during the disease process and examine the correlation with various disease parameters.

NCT ID: NCT01903122 Completed - Dry Mouth Clinical Trials

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Start date: February 2009
Phase: Early Phase 1
Study type: Interventional

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions

NCT ID: NCT01903109 Completed - Dry Mouth Clinical Trials

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Start date: February 2009
Phase: Early Phase 1
Study type: Interventional

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions

NCT ID: NCT01885065 Completed - Cancer Clinical Trials

Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients

Start date: July 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether continuous use of edible, gel-based artificial saliva in cancer patients with dry mouth problems will reduce signs and symptoms of dry mouth and improve quality of patients' saliva.

NCT ID: NCT01737307 Completed - Infection Clinical Trials

Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the effect of Fluoride varnish and Casein Phospho-Peptide Amorphous Calcium Phosphate (CPP-ACP) containing paste on oral symptoms and salivary characteristics in patients under chemotherapy.

NCT ID: NCT01690052 Completed - Dry Mouth Clinical Trials

Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva

Start date: January 2009
Phase: N/A
Study type: Interventional

The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.

NCT ID: NCT01647737 Completed - Xerostomia Clinical Trials

Green Tea Lozenges for the Management of Dry Mouth

Start date: March 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia patent pending formulation of natural plant extracts on patients with xerostomia. The major component of this formulation is green tea extract with a defined composition of polyphenols. Epidemiological studies suggest that phytochemicals in green tea possess beneficial effects on autoimmune and inflammatory diseases. Thus far, there is little evidence to indicate any marked and direct immunomodulatory effect of green tea on T or B lymphocytes. However, there is considerable evidence for green tea polyphenols (GTPs), major phytochemicals found in green tea extract, having properties consistent with effects on cells of tissues that would be protective towards local inflammation.

NCT ID: NCT00618059 Completed - Dry Mouth Clinical Trials

Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions

Start date: August 2004
Phase: N/A
Study type: Interventional

The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

NCT ID: NCT00602524 Completed - Dry Mouth Clinical Trials

Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions

Start date: August 2004
Phase: N/A
Study type: Interventional

The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

NCT ID: NCT00601874 Completed - Dry Mouth Clinical Trials

Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions

Start date: September 2003
Phase: N/A
Study type: Interventional

The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.